Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
Nat Med
.
2022 Apr;28(4):871.
doi: 10.1038/s41591-022-01771-w.
Authors
Julie Westerlin Kjeldsen
#
1
,
Cathrine Lund Lorentzen
#
1
,
Evelina Martinenaite
1
2
,
Eva Ellebaek
1
,
Marco Donia
1
,
Rikke Boedker Holmstroem
1
,
Tobias Wirenfeldt Klausen
1
,
Cecilie Oelvang Madsen
1
,
Shamaila Munir Ahmed
1
,
Stine Emilie Weis-Banke
1
,
Morten Orebo Holmström
1
,
Helle Westergren Hendel
3
,
Eva Ehrnrooth
2
,
Mai-Britt Zocca
2
,
Ayako Wakatsuki Pedersen
2
,
Mads Hald Andersen
1
4
,
Inge Marie Svane
5
Affiliations
1
National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
2
IO Biotech Aps, Copenhagen, Denmark.
3
Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Herlev, Denmark.
4
Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
5
National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
[email protected]
.
#
Contributed equally.
PMID:
35260843
PMCID:
PMC9018417
DOI:
10.1038/s41591-022-01771-w
No abstract available
Publication types
Published Erratum